Page 173 - Read Online

Belizario et al. Cancer Drug Resist 2019;2:527-38 I http://dx.doi.org/10.20517/cdr.2018.009 Page 537

Rev Genet 2016;17:284-99.
13. Roy DM, Walsh LA, Chan TA. Driver mutations of cancer epigenomes. Protein Cell 2014;5:265-96.
14. Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: A historical perspective. Nat Rev Cancer 2016;16:35-42.
15. Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: prospects and challenges. Trends Genet 2014;30:75-84.
16. Yao L, Shen H, Laird PW, Farnham PJ, Berman BP. Inferring regulatory element landscapes and transcription factor networks from
cancer methylomes. Genome Biol. 2015;16:105.
17. Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, et al. Epigenome-based cancer risk prediction: rationale, opportunities and
challenges. Nat Rev Clin Oncol 2018;15:292-309.
18. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug
Discov 2015;14:561-84.
19. Blank CU, Haanen JB, Ribas A, Schumacher TN. Cancer Immunology. The cancer Immunogram. Science 2016;352:658-60.
20. Dumont N, Liu B, DeFilippis RA, Chang H, Rabban JT. Breast fibroblasts modulate early dissemination, tumorigenesis, and
metastasis through alteration of extracellular matrix characteristics. Neoplasia 2013;15:249.
21. Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, et al. The immune landscape of cancer. Immunity 2018;48:812-30.
22. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005;15:494-501.
23. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, et al. Heterogeneity for stem cell-related markers according to tumor subtype and
histologic stage in breast cancer. Clin Cancer Res 2010;16:876-87.
24. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119:1420-8.
25. Aparicio S, Mardis E. Tumor heterogeneity: next-generation sequencing enhances the view from pathologist’s microscope. Genome
Biol 2014;15:463.
26. Laskin J, Jones S, Aparicio S, Chia S, Ch’ng C, et al. Lessons learned from the application of whole-genome analysis to the treatment
of patients with advanced cancers. Cold Spring Harb Mol Case Stud 2015;1:a000570.
27. Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, et al. Proteogenomics connects somatic mutations to signaling in breast
cancer. Nature 2016;534:55-62.
28. Guerin M, Gonçalves A, Toiron Y, Baudelet E, Audebert S, et al. How may targeted proteomics complement genomic data in breast
cancer? Expert Rev Proteomics 2017;14:43-54.
29. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. Molecular definition of breast tumor heterogeneity.
Cancer Cell 2007;11:259-73.
30. Reis-Filho J, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet
2011;378:1812-23.
31. Gudjonsson T, Adriance MC, Sternlicht MD, Petersen OW, Bissel MJ. Myoepithelial cells: their origin and function in breast
morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 2005;10:261-72.
32. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. The landscape of cancer genes and mutational processes in breast
cancer. Nature 2012;486:400-4.
33. Sorlie T, Tibshirani R, Parker J, Hastie H, Marron JS, et al. Repeated observation of breast tumor subtypes in independent gene
expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
34. Curtis CSP, Shah SF, Chin G, Turashvili OM, Rueda MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours
reveals novel subgroups. Nature 2012;486:346-52.
35. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-
52.
36. De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, et al. Genetic heterogeneity and actionable mutations in
HER2-positive primary breast cancers and their brain metastases. Oncotarget 2018;9:20617-30.
37. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006;25:5846-53.
38. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer.
Adv Exp Med Biol 2007;608:1-22.
39. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, et al. The genomic landscape of endocrine-resistant advanced breast cancers.
Cancer Cell 2018;34:427-38.
40. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, et al. Treatment of HER2-positive breast cancer: current status and
future perspectives. Nat Rev Clin Oncol 2012;9:16-32.
41. Pareja F, Reis-Filho JS. Triple-negative breast cancers - a panoply of cancer types. Nat Rev Clin Oncol 2018;15:347-8.
42. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
43. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio AS, Behjati S, et al. Signatures of mutational processes in human cancer. Nature
2013;500:415-21.
44. Mundim FG, Pasini FS, Nonogaki S, Rocha RM, Soares FA, et al. Breast carcinoma-associated fibroblasts share similar biomarker
profiles in matched lymph node metastasis. Appl Immunohistochem Mol Morphol 2016;24:712-20.
45. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy
for women with early-stage Invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol
2016;34:1134-50.
46. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, et al. Effect of occult metastases on survival in node-negative breast
cancer. N Engl J Med 2011;364:412-21.